Thetis Receives Funds From Crohn’s & Colitis Foundation to Further Develop TP-317 for IBD

Thetis Receives Funds From Crohn’s & Colitis Foundation to Further Develop TP-317 for IBD
The Crohn's & Colitis Foundation is providing funding support to Thetis Pharmaceuticals for the continuing development of the novel oral therapy TP-317 for the treatment of inflammatory bowel disease (IBD). "We very much appreciate the support of the Crohn's & Colitis Foundation and their confidence in our team and the promise of our Resolvin-based therapy as a novel approach to treatment of IBD," Gary Mathias, CEO of Thetis, said in a press release. TP-317 is a novel and optimized formulation of the bioactive natural fatty molecule resolvin E1, which was first discovered by Charles Serhan, PhD, professor at Harvard University and researcher at Brigham and Women's Hospital. Resolvin E1, also known as RvE1, is a byproduct of omega-3 fatty acid metabolism and was found to have the ability to regulate several mechanisms involved in tissue inflammation and repair implicated in IBD progression. In contrast to other molecules that can inhibit immune-mediated damage, RvE1 can block the same processes without affecting the body's natural and necessary immune defenses. "Resolvin E1 is a potent bioactive lipid mediator produced locally in inflamed tissue to orchestrate resolution of inflammation, reduction of pain and tissue repair following initiation of an acute inflammatory response," said Serhan, who is also scientific advisor to Thetis. "In chronic inflammatory diseases such as IBD, defective resolution leads to unresolved inflammation, tissue damage, and pain. Novel therapeutic approaches leveraging the pharmacology of Resolvins offer a unique, non-immunosuppressive approach to treating IBD by activating intrinsic resolution mechanisms in the body," he said. Results from preclinical studies using several animal models of IBD demonstrated that TP-31
Subscribe or to access all post and page content.